• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Prostate Cancer – Clinical Trials – Efficacy and Side Effects by Reporting Groups – Reference Directory, Comparison Guide, Database & Handbook Product Image

Prostate Cancer – Clinical Trials – Efficacy and Side Effects by Reporting Groups – Reference Directory, Comparison Guide, Database & Handbook

  • Published: January 2013
  • Region: United States
  • 138 Pages
  • PharmaFlare

FEATURED COMPANIES

  • Astrazeneca
  • Bristol-Myers Squibb
  • Dendreon
  • Eisai
  • Ferring Pharmaceuticals
  • Glaxosmithkline
  • MORE

PharmaFlare’s pharmaceutical report, Prostate Cancer - Clinical Trials - Efficacy and Side Effects by Reporting Groups - Reference Directory, Comparison Guide, Database & Handbook is a comprehensive compilation of all Prostate cancer completed clinical trials by reporting group. The report offers comprehensive data set at the most atomic level of prostate cancer clinical trials & is the basis for FDA approvals & prescription choices. It also includes information and data relating to study details, phase, efficacy and safety comparison, sponsor, investigator, collaborator, and other key parameters. The report is built using data and information sourced from multiple data sources.
Scope:

- Data on the number of clinical trials conducted in the US

- Completed clinical trials data by reporting group, phase, sponsor, number of patients recruited and investigator details

- Efficacy and safety comparison by reporting groups
Who should buy this type of report?

- Pharma Companies

- Hospitals

- Insurance Companies

- Investors and Venture Capitalists

- Industry Analysts & Consultants

- Industry association

- READ MORE >

1.1.1 List of Tables

2 Clinical Trial 1. Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
2.1 Study Details:
2.2 Efficacy and Safety Details:
2.2.1 Efficacy Reporting Groups & Description:
2.2.2 Efficacy Comparison
2.2.3 Safety Reporting Groups & Description:
2.2.4 Safety Comparison

3 Clinical Trial 2. Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
3.1 Study Details:
3.2 Efficacy and Safety Details:
3.2.1 Efficacy Reporting Groups & Description:
3.2.2 Efficacy Comparison
3.2.3 Safety Reporting Groups & Description:
3.2.4 Safety Comparison

4 Clinical Trial 3. Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
4.1 Study Details:
4.2 Efficacy and Safety Details:
4.2.1 Efficacy Reporting Groups & Description:
4.2.2 Efficacy Comparison
4.2.3 Safety Reporting Groups & Description:
4.2.4 Safety Comparison

5 Clinical Trial 4. Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
5.1 Study Details:
5.2 Efficacy and Safety Details:
5.2.1 Efficacy Reporting Groups & Description:
5.2.2 Efficacy Comparison
5.2.3 Safety Reporting Groups & Description:
5.2.4 Safety Comparison

6 Clinical Trial 5. A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
6.1 Study Details:
6.2 Efficacy and Safety Details:
6.2.1 Efficacy Reporting Groups & Description:
6.2.2 Efficacy Comparison
6.2.3 Safety Reporting Groups & Description:
6.2.4 Safety Comparison

7 Clinical Trial 6. ""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
7.1 Study Details:
7.2 Efficacy and Safety Details:
7.2.1 Efficacy Reporting Groups & Description:
7.2.2 Efficacy Comparison
7.2.3 Safety Reporting Groups & Description:
7.2.4 Safety Comparison

8 Clinical Trial 7. Sequential Vaccinations in Prostate Cancer Patients
8.1 Study Details:
8.2 Efficacy and Safety Details:
8.2.1 Efficacy Reporting Groups & Description:
8.2.2 Efficacy Comparison
8.2.3 Safety Reporting Groups & Description:
8.2.4 Safety Comparison

9 Clinical Trial 8. Provenge (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
9.1 Study Details:
9.2 Efficacy and Safety Details:
9.2.1 Efficacy Reporting Groups & Description:
9.2.2 Efficacy Comparison
9.2.3 Safety Reporting Groups & Description:
9.2.4 Safety Comparison

10 Clinical Trial 9. ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
10.1 Study Details:
10.2 Efficacy and Safety Details:
10.2.1 Efficacy Reporting Groups & Description:
10.2.2 Efficacy Comparison
10.2.3 Safety Reporting Groups & Description:
10.2.4 Safety Comparison

11 Clinical Trial 10. A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
11.1 Study Details:
11.2 Efficacy and Safety Details:
11.2.1 Efficacy Reporting Groups & Description:
11.2.2 Efficacy Comparison
11.2.3 Safety Reporting Groups & Description:
11.2.4 Safety Comparison

12 Clinical Trial 11. A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
12.1 Study Details:
12.2 Efficacy and Safety Details:
12.2.1 Efficacy Reporting Groups & Description:
12.2.2 Efficacy Comparison
12.2.3 Safety Reporting Groups & Description:
12.2.4 Safety Comparison

13 Clinical Trial 12. A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
13.1 Study Details:
13.2 Efficacy and Safety Details:
13.2.1 Efficacy Reporting Groups & Description:
13.2.2 Efficacy Comparison
13.2.3 Safety Reporting Groups & Description:
13.2.4 Safety Comparison

14 Clinical Trial 13. Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
14.1 Study Details:
14.2 Efficacy and Safety Details:
14.2.1 Efficacy Reporting Groups & Description:
14.2.2 Efficacy Comparison
14.2.3 Safety Reporting Groups & Description:
14.2.4 Safety Comparison

15 Clinical Trial 14. Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
15.1 Study Details:
15.2 Efficacy and Safety Details:
15.2.1 Efficacy Reporting Groups & Description:
15.2.2 Efficacy Comparison
15.2.3 Safety Reporting Groups & Description:
15.2.4 Safety Comparison

16 Clinical Trial 15. Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
16.1 Study Details:
16.2 Efficacy and Safety Details:
16.2.1 Efficacy Reporting Groups & Description:
16.2.2 Efficacy Comparison
16.2.3 Safety Reporting Groups & Description:
16.2.4 Safety Comparison

17 Clinical Trial 16. Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
17.1 Study Details:
17.2 Efficacy and Safety Details:
17.2.1 Efficacy Reporting Groups & Description:
17.2.2 Efficacy Comparison
17.2.3 Safety Reporting Groups & Description:
17.2.4 Safety Comparison

18 Clinical Trial 17. GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
18.1 Study Details:
18.2 Efficacy and Safety Details:
18.2.1 Efficacy Reporting Groups & Description:
18.2.2 Efficacy Comparison
18.2.3 Safety Reporting Groups & Description:
18.2.4 Safety Comparison

19 Clinical Trial 18. Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
19.1 Study Details:
19.2 Efficacy and Safety Details:
19.2.1 Efficacy Reporting Groups & Description:
19.2.2 Efficacy Comparison
19.2.3 Safety Reporting Groups & Description:
19.2.4 Safety Comparison

20 Clinical Trial 19. Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
20.1 Study Details:
20.2 Efficacy and Safety Details:
20.2.1 Efficacy Reporting Groups & Description:
20.2.2 Efficacy Comparison
20.2.3 Safety Reporting Groups & Description:
20.2.4 Safety Comparison

21 Clinical Trial 20. Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
21.1 Study Details:
21.2 Efficacy and Safety Details:
21.2.1 Efficacy Reporting Groups & Description:
21.2.2 Efficacy Comparison
21.2.3 Safety Reporting Groups & Description:
21.2.4 Safety Comparison

22 Clinical Trial 21. The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
22.1 Study Details:
22.2 Efficacy and Safety Details:
22.2.1 Efficacy Reporting Groups & Description:
22.2.2 Efficacy Comparison
22.2.3 Safety Reporting Groups & Description:
22.2.4 Safety Comparison

23 Clinical Trial 22. Study of SU11248 in Men With Advanced Prostate Cancer
23.1 Study Details:
23.2 Efficacy and Safety Details:
23.2.1 Efficacy Reporting Groups & Description:
23.2.2 Efficacy Comparison
23.2.3 Safety Reporting Groups & Description:
23.2.4 Safety Comparison

24 Clinical Trial 23. Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
24.1 Study Details:
24.2 Efficacy and Safety Details:
24.2.1 Efficacy Reporting Groups & Description:
24.2.2 Efficacy Comparison
24.2.3 Safety Reporting Groups & Description:
24.2.4 Safety Comparison
25 Clinical Trial 24. Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
25.1 Study Details:
25.2 Efficacy and Safety Details:
25.2.1 Efficacy Reporting Groups & Description:
25.2.2 Efficacy Comparison
25.2.3 Safety Reporting Groups & Description:
25.2.4 Safety Comparison

26 Clinical Trial 25. XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
26.1 Study Details:
26.2 Efficacy and Safety Details:
26.2.1 Efficacy Reporting Groups & Description:
26.2.2 Efficacy Comparison
26.2.3 Safety Reporting Groups & Description:
26.2.4 Safety Comparison

27 Clinical Trial 26. Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
27.1 Study Details:
27.2 Efficacy and Safety Details:
27.2.1 Efficacy Reporting Groups & Description:
27.2.2 Efficacy Comparison
27.2.3 Safety Reporting Groups & Description:
27.2.4 Safety Comparison

28 Clinical Trial 27. Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
28.1 Study Details:
28.2 Efficacy and Safety Details:
28.2.1 Efficacy Reporting Groups & Description:
28.2.2 Efficacy Comparison
28.2.3 Safety Reporting Groups & Description:
28.2.4 Safety Comparison
29 Clinical Trial 28. Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
29.1 Study Details:
29.2 Efficacy and Safety Details:
29.2.1 Efficacy Reporting Groups & Description:
29.2.2 Efficacy Comparison
29.2.3 Safety Reporting Groups & Description:
29.2.4 Safety Comparison

30 Clinical Trial 29. Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
30.1 Study Details:
30.2 Efficacy and Safety Details:
30.2.1 Efficacy Reporting Groups & Description:
30.2.2 Efficacy Comparison
30.2.3 Safety Reporting Groups & Description:
30.2.4 Safety Comparison

31 Clinical Trial 30. A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
31.1 Study Details:
31.2 Efficacy and Safety Details:
31.2.1 Efficacy Reporting Groups & Description:
31.2.2 Efficacy Comparison
31.2.3 Safety Reporting Groups & Description:
31.2.4 Safety Comparison

32 Clinical Trial 31. A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
32.1 Study Details:
32.2 Efficacy and Safety Details:
32.2.1 Efficacy Reporting Groups & Description:
32.2.2 Efficacy Comparison
32.2.3 Safety Reporting Groups & Description:
32.2.4 Safety Comparison

33 Clinical Trial 32. A Study of Leuprolide to Treat Prostate Cancer
33.1 Study Details:
33.2 Efficacy and Safety Details:
33.2.1 Efficacy Reporting Groups & Description:
33.2.2 Efficacy Comparison
33.2.3 Safety Reporting Groups & Description:
33.2.4 Safety Comparison

34 Clinical Trial 33. Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
34.1 Study Details:
34.2 Efficacy and Safety Details:
34.2.1 Efficacy Reporting Groups & Description:
34.2.2 Efficacy Comparison:
34.2.3 Safety Reporting Groups & Description:
34.2.4 Safety Comparison

35 Clinical Trial 34. Green Tea Extract and Prostate Cancer
35.1 Study Details:
35.2 Efficacy and Safety Details:
35.2.1 Efficacy Reporting Groups & Description:
35.2.2 Efficacy Comparison
35.2.3 Safety Reporting Groups & Description:
35.2.4 Safety Comparison

36 Clinical Trial 35. Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
36.1 Study Details:
36.2 Efficacy and Safety Details:
36.2.1 Efficacy Reporting Groups & Description:
36.2.2 Efficacy Comparison
36.2.3 Safety Reporting Groups & Description:
36.2.4 Safety Comparison

37 Clinical Trial 36. Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
37.1 Study Details:
37.2 Efficacy and Safety Details:
37.2.1 Efficacy Reporting Groups & Description:
37.2.2 Efficacy Comparison
37.2.3 Safety Reporting Groups & Description:
37.2.4 Safety Comparison

38 Clinical Trial 37. Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
38.1 Study Details:
38.2 Efficacy and Safety Details:
38.2.1 Efficacy Reporting Groups & Description:
38.2.2 Efficacy Comparison
38.2.3 Safety Reporting Groups & Description:
38.2.4 Safety Comparison
38.3 About PharmaFlare
38.4 Contact Us
38.5 Disclaimer

- Dendreon
- Astrazeneca
- Glaxosmithkline
- Ferring Pharmaceuticals
- Pfizer
- Eisai
- Sanofi
- Bristol-Myers Squibb

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos